Diana Brixner

All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective

Carrie McAdam‐Marx, Lisa J. McGarry, Christopher A. Hane et al. · Journal of Managed Care Pharmacy · 2011 · 168 citations · Full text

Medicine, Pharmacoeconomics, Health Services Research +15

The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy

Diana Brixner, Eman Biltaji, Adam P. Bress et al. · Journal of Medical Economics · 2015 · 151 citations

Pharmacy, Pharmacoeconomics, Pharmacology +17

Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group

E.C. Faulkner, Anke‐Peggy Holtorf, Surrey M. Walton et al. · Value in Health · 2020 · 113 citations · Full text

Pharmacy, Molecular Medicine, Translational Sciences +15

Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting

Carrie McAdam‐Marx, Xiangyang Ye, Jennifer Sung et al. · Clinical Therapeutics · 2009 · 90 citations

Medicine, Cardiology, Internal Medicine +17

Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations

Diana Brixner, Kenneth C. Jackson, Xiaoming Sheng et al. · Current Medical Research and Opinion · 2008 · 87 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17